ClinicalTrials.gg

Program

apatinib

Also written as “Apatinib”, “Rivoceranib” and “Apatinib Mesylate”.

Its studies are mostly in Stomach Neoplasms · Ovarian Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung, led by 8 companies.

Furthest: phase 3, since Jan 13, 201247 company-led studies, 8 open or runningNext primary completion: Dec 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine344 open or runningphase 3since Jan 13, 2012Aug 30, 2010none ahead
Elevar Therapeutics70 open or runningphase 3since Jan 24, 2017Dec 18, 2011none ahead
Bukwang Pharmaceutical10 open or runningphase 1since Feb 26, 2016Feb 26, 2016none ahead
GrandPharma (China)11 open or runningphase 2since Aug 13, 2025Aug 13, 2025Dec 30, 2027phase 2 · NCT07334483
Guangzhou Virotech Pharmaceutical11 open or runningphase 3since May 8, 2026May 8, 2026Dec 31, 2028phase 3 · NCT07589244
Hansoh Pharmaceutical Group11 open or runningphase 1since Jan 7, 2025Jan 7, 2025none ahead
HRYZ Biotech11 open or runningearly phase 1since Aug 26, 2019Aug 26, 2019none ahead
Qilu Pharmaceutical10 open or runningphase 2since Aug 14, 2017Aug 14, 2017none ahead

Also a collaborator on its studies: bukwang-pharmaceutical-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 32 studies since Aug 30, 2010.

  1. Apr 8, 2020Phase 1 study in Healthy SubjectsJiangsu HengRui Medicine · NCT04341090 · 42 enrolled · China
  2. Apr 9, 2020Phase 3 study in Stomach NeoplasmsJiangsu HengRui Medicine · NCT04342910 · 550 planned · China
  3. May 6, 2020Phase 2 study in Ovarian NeoplasmsJiangsu HengRui Medicine · NCT04383977 · 54 enrolled
  4. May 13, 2020Phase 1 study in NSCLCJiangsu HengRui Medicine · NCT04390984 · 22 enrolled · China
  5. Jun 1, 20202 phase 1 studiesJiangsu HengRui Medicine · NCT04414852, NCT04457180
  6. Aug 16, 2020Phase 2 study in Ovarian NeoplasmsJiangsu HengRui Medicine · NCT04517357 · 100 enrolled · China
  7. Nov 19, 2020Phase 3 study in Carcinoma, HepatocellularJiangsu HengRui Medicine · NCT04639180 · 687 enrolled · China
  8. Apr 26, 2021Phase 2 study in Metastatic Castration Resistant Prostate CancerJiangsu HengRui Medicine · NCT04869488 · 93 enrolled · China
  9. Jul 15, 2021Phase 3 study in Advanced Hepatocellular Carcinoma (HCC)Jiangsu HengRui Medicine · NCT04985136 · 1 enrolled · China
  10. Mar 10, 2022Phase 1 study in HealthyElevar Therapeutics · NCT05287360 · 60 enrolled · United States
  11. Apr 2, 2022Phase 3 study in Carcinoma, HepatocellularJiangsu HengRui Medicine · NCT05320692 · 423 enrolled · China
  12. Jan 7, 2025Hansoh Pharmaceutical Group's first study: phase 1 study in Ovarian NeoplasmsNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT06769425 · 157 planned · China
  13. Aug 13, 2025GrandPharma (China)'s first study: phase 2 study in HCCNew to GrandPharma (China)GrandPharma (China) · NCT07334483 · 120 planned · China
  14. May 8, 2026Guangzhou Virotech Pharmaceutical's first study: phase 3 study in HCCNew to Guangzhou Virotech PharmaceuticalGuangzhou Virotech Pharmaceutical · NCT07589244 · 66 planned · China

Ahead

  1. Dec 30, 2027Primary completion: phase 2 study in HCCGrandPharma (China) · NCT07334483
  2. Dec 31, 2028Primary completion: phase 3 study in HCCGuangzhou Virotech Pharmaceutical · NCT07589244

TargetBeta

KDR →read by rule
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule

Other programs on KDR

ProgramCompanyFurthest phaseStudies
lenvatinibruleEisaiphase 481
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
cabozantinibruleExelixisphase 436
RamucirumabruleEli Lillyphase 358
AxitinibrulePfizerphase 345
anlotinibruleSino Biopharmaceuticalphase 340
vorolanibruleBetta Pharmaceuticalsphase 324
zanzalintinibruleExelixisphase 317
chiauranibruleChipscreen Biosciencesphase 315
Aurora B/VEGFR/FGFR Inhibitor AL8326ruleadvenchen-laboratories-nanjing-ltdphase 38
AXL/FLT3/VEGFR2 Inhibitor KC1036rulebeijing-konruns-pharmaceutical-co-ltdphase 37

Studies

All 47 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07589244HCC · China3RecruitingGuangzhou Virotech PharmaceuticalDec 31, 202866
NCT07334483HCC · China2RecruitingGrandPharma (China)Dec 30, 2027120
NCT06769425Ovarian Neoplasms · China1RecruitingHansoh Pharmaceutical GroupMay 7, 2026157
NCT05320692Carcinoma, Hepatocellular · China3Active, not recruitingJiangsu HengRui MedicineJul 30, 2026423
NCT05287360Healthy · United States1CompletedElevar TherapeuticsMar 16, 202260
NCT04985136Advanced Hepatocellular Carcinoma (HCC) · China3TerminatedJiangsu HengRui MedicineDec 29, 20211
NCT04869488Metastatic Castration Resistant Prostate Cancer · China2CompletedJiangsu HengRui MedicineFeb 14, 202393
NCT04639180Carcinoma, Hepatocellular · China3Active, not recruitingJiangsu HengRui MedicineJul 31, 2026687
NCT04517357Ovarian Neoplasms · China2CompletedJiangsu HengRui MedicineNov 30, 2023100
NCT04457180Advanced Solid Tumor · China1CompletedJiangsu HengRui MedicineMay 20, 202118
NCT04414852Subjects With Impaired Renal Function and Healthy Subjects1UNKNOWNJiangsu HengRui MedicineJan 15, 202124
NCT04390984NSCLC · China1UNKNOWNJiangsu HengRui MedicineFeb 202122
NCT04383977Ovarian Neoplasms2UNKNOWNJiangsu HengRui MedicineDec 202054
NCT04342910Stomach Neoplasms · China3RecruitingJiangsu HengRui MedicineApr 1, 2026550
NCT04341090Healthy Subjects · China1CompletedJiangsu HengRui MedicineJul 6, 202042
NCT04335006Breast Neoplasms · China3TerminatedJiangsu HengRui MedicineApr 14, 202380
NCT04322552Advanced Solid Tumor · China1CompletedJiangsu HengRui MedicineApr 3, 202118
NCT04296370Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation · China3RecruitingJiangsu HengRui MedicineJun 30, 2022474
NCT04229615Ovarian Neoplasms · China3UNKNOWNJiangsu HengRui MedicineJun 30, 2023690
NCT04203485PD-L1 Positive Non-small Cell Lung Cancer3UNKNOWNJiangsu HengRui MedicineMar 31, 2022762
NCT04119453Carcinoma, Adenoid Cystic · United States, South Korea2TerminatedElevar TherapeuticsJun 28, 202380
NCT04074564Sarcoma · ChinaEarly 1RecruitingHRYZ BiotechAug 7, 202460
NCT04073615Colorectal Neoplasms · United States1TerminatedElevar TherapeuticsMay 31, 202329
NCT04000295Ovarian Neoplasms · China3UNKNOWNJiangsu HengRui MedicineJan 2021280
NCT03945604Triple Negative Breast Neoplasms · China1CompletedJiangsu HengRui MedicineFeb 9, 202132
NCT03711279Sarcoma · China2TerminatedJiangsu HengRui MedicineJun 21, 202199
NCT03707028Stomach Neoplasms · Korea, Republic of2TerminatedElevar TherapeuticsAug 24, 202112
NCT03491631Neoplasms · China1UNKNOWNJiangsu HengRui MedicineJun 202323
NCT03472365Stomach Neoplasms · China2CompletedJiangsu HengRui MedicineNov 25, 202067
NCT03463876Carcinoma, Hepatocellular · China2CompletedJiangsu HengRui MedicineMar 10, 2021190
NCT03396211Neoplasms · United States1CompletedElevar TherapeuticsOct 28, 202030
NCT03267654Carcinoma, Non-Small-Cell Lung · China2UNKNOWNQilu PharmaceuticalOct 20, 2020100
NCT03245307Cytochrome P450 Interaction · China1UNKNOWNJiangsu HengRui MedicineApr 30, 201820
NCT03075462Ovarian Neoplasms · China1CompletedJiangsu HengRui MedicineAug 22, 202198
NCT03042611Stomach Neoplasms · United States, France, Germany and more3CompletedElevar TherapeuticsFeb 15, 2019460
NCT03026881Recurrence · China1UNKNOWNJiangsu HengRui MedicineApr 201824
NCT02836171Neoplasms · China1CompletedJiangsu HengRui MedicineFeb 201720
NCT02836821Neoplasms · China1CompletedJiangsu HengRui MedicineFeb 201720
NCT02764268Stomach Neoplasms · China–CompletedJiangsu HengRui MedicineDec 10, 201860
NCT02711969Stomach Neoplasms · Korea, Republic of1CompletedBukwang PharmaceuticalNov 20166
NCT02332512Carcinoma, Non-Small-Cell Lung · China3UNKNOWNJiangsu HengRui MedicineAug 2017417
NCT02329860Carcinoma, Hepatocellular · China3CompletedJiangsu HengRui MedicineDec 15, 2017400
NCT01531777Colorectal Neoplasms · China2CompletedJiangsu HengRui MedicineNov 201440
NCT01512745Stomach Neoplasms · China3CompletedJiangsu HengRui MedicineMay 2013267
NCT01497704Neoplasms · United States, Korea, Republic of2CompletedElevar TherapeuticsFeb 201555
NCT01270386Carcinoma, Non-Small-Cell Lung · China2CompletedJiangsu HengRui MedicineJul 2011136
NCT01192971Neoplasms · China2CompletedJiangsu HengRui MedicineJul 2013121

How it is read

Names in the registry

  • “Apatinib”, 13 entries
  • “Rivoceranib”, 5 entries
  • “Apatinib Mesylate”, 5 entries
  • “apatinib”, 3 entries
  • “Fluzoparib+Apatinib”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.